DOI: http://dx.doi.org/10.18203/2349-3933.ijam20172269

The effect of nevirapine vs efavirenz containing regimens on clinical outcomes among HIV patients on ART: a comparative study

Jeetam Singh Rajput, Manoj Kumar Mathur, Ajeet Kumar Chaurasia, Smriti Singh, Alankar Tiwari

Abstract


Background: The present study has been conducted to compare regimens containing either of nevirapine (NVP) and efavirenz (EFV) and two or more nucleoside reverse transcriptase inhibitors (NRTIs) among HIV infected patients in respect to clinical outcome and to compare incidence of opportunistic infections among these patients.

Methods: This study was an observational study conducted at a tertiary care centre over 105 patients, who were evenly matched and received three antiretroviral drug one of the drug was either nevirapine (NVP) or efavirenz (EFV) and these patients were followed up for 6 months for occurrence of any opportunistic infections during these 6 months.

Results: 105 patients were followed for 6 months, the maximum incidence of opportunistic infection (OI’s) was found among patients who were on ZLN (zidovudine, lamivudine, nevirapine) regime i.e. 60% followed by patients who changed their regime from ZLN to TLE i.e. 36.5%, while the least incidence of OI’s was noted among the patients who were on TLE (tenofovir, lamivudine, efavirenz) regime i.e. 28.5%. These differences were found to be statistically significant (p<0.05).

Conclusions: EFV containing antiretroviral regimen was associated with superior clinical outcome than NVP containing regimen.


Keywords


Efavirenz, Nevirapine, Opportunistic infections, ZLN and TLE regime

Full Text:

PDF

References


National AIDS control program phase 4; 2014.

World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Available from: http:// www.who.int/ hiv/pub/arv/rapid advice art.pdf.2009

European AIDS Clinical Society. EACS Guidelines. Available from: http://www.Europeanaids clinicalsociety.org/images/stories/EACS-Pdf/ eacsguidelines/v6/english.pdf.2011.

Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al. 1; British HIV Association Guidelines for the treatment of HIV- 1-infected adults with antiretroviral therapy 2008. HIVMed. 2008;9:563-608.

Mbuagbaw LCE, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naı¨ve individuals. Cochrane Database Syst Rev. 2010;12:CD004246.

Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, et al. Viral load outcome of nonnucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS. 2001;15:2385-95.

Cozzi-Lepri A, Phillips AN, d’Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N. A.) study. J Infect Dis. 2002;185:1062-9.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: A cohort study. AIDS. 2002;16:53-61.

Keiser P, Nassar N, White C, Koen G, Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials. 2002;3:296-303.

Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, et al. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. Antivi Ther. 2007;12:317-24.

Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22:2117-25.

Hartmann M, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). Int J STD AIDS. 2005;16:404-9.

The Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis. 2006;194:612-22.

Pujari S, Patel A, Naik E. Effectiveness of generic fixed-dose combination of HAART for treatment of HIV infection in India. J Acquir immune defic syndr. 2004;4:110.

Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, Godbole S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13(1):e1-8.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, et al. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS. 2012;26(13):1691-705.

Cain LE, Hernán MA. HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results. AIDS. 2012;26(16):2117-8.